CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Takeda Pharmaceutical Company Limited - 4502 CFD

4126.03
0.08%
Market Trading Hours* (UTC) Opens on Monday at 00:00

Mon - Fri: 00:00 - 02:30 03:30 - 06:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 23.64
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.011244 %
Charges from full value of position ($-2.14)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.011244%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.010978 %
Charges from full value of position ($-2.09)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.010978%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency JPY
Margin 5%
Stock exchange Japan
Commission on trade 0%

*Information provided by Capital.com

Takeda Pharmaceutical Co Ltd ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 4129.32
Open* 4115.35
1-Year Change* -6.01%
Day's Range* 4114.36 - 4139.29
52 wk Range 3,900.00-4,873.00
Average Volume (10 days) 5.00M
Average Volume (3 months) 83.99M
Market Cap 6,938.79B
P/E Ratio 35.96
Shares Outstanding 1.57B
Revenue 4,154.41B
EPS 121.95
Dividend (Yield %) 4.19612
Beta 1.00
Next Earnings Date Feb 1, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 12, 2024 4126.03 8.48 0.21% 4117.55 4141.49 4109.87
Apr 11, 2024 4127.22 2.49 0.06% 4124.73 4152.46 4121.73
Apr 10, 2024 4137.10 -17.54 -0.42% 4154.64 4169.11 4134.31
Apr 9, 2024 4149.76 -2.98 -0.07% 4152.74 4158.74 4123.23
Apr 8, 2024 4139.49 21.15 0.51% 4118.34 4141.29 4105.38
Apr 5, 2024 4105.98 23.17 0.57% 4082.81 4117.75 4079.75
Apr 4, 2024 4096.00 -10.87 -0.26% 4106.87 4118.75 4091.52
Apr 3, 2024 4091.32 0.90 0.02% 4090.42 4102.49 4058.50
Apr 2, 2024 4124.13 -13.16 -0.32% 4137.29 4154.55 4094.90
Apr 1, 2024 4145.28 -45.87 -1.09% 4191.15 4198.43 4139.78
Mar 29, 2024 4177.59 -9.48 -0.23% 4187.07 4188.16 4164.33
Mar 28, 2024 4192.55 -101.34 -2.36% 4293.89 4298.28 4187.06
Mar 27, 2024 4381.66 5.99 0.14% 4375.67 4401.31 4368.19
Mar 26, 2024 4370.59 42.30 0.98% 4328.29 4379.17 4310.34
Mar 25, 2024 4354.13 -39.50 -0.90% 4393.63 4394.82 4346.24
Mar 22, 2024 4398.52 32.82 0.75% 4365.70 4406.79 4355.32
Mar 21, 2024 4369.69 -6.18 -0.14% 4375.87 4404.30 4359.31
Mar 19, 2024 4354.32 16.96 0.39% 4337.36 4362.01 4327.39
Mar 18, 2024 4350.74 23.35 0.54% 4327.39 4364.70 4320.41
Mar 15, 2024 4291.49 9.47 0.22% 4282.02 4325.00 4272.54

Takeda Pharmaceutical Company Limited Events

Time (UTC) Country Event
Thursday, June 27, 2024

Time (UTC)

01:00

Country

JP

Event

Takeda Pharmaceutical Co Ltd Annual Shareholders Meeting
Takeda Pharmaceutical Co Ltd Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, July 31, 2024

Time (UTC)

06:00

Country

JP

Event

Q1 2025 Takeda Pharmaceutical Co Ltd Earnings Release
Q1 2025 Takeda Pharmaceutical Co Ltd Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total revenue 4027480 3569010 3197810 3291190 2097220
Revenue 4027480 3569010 3197810 3291190 2097220
Cost of Revenue, Total 1244070 1106850 994308 1089760 651729
Gross Profit 2783410 2462160 2203500 2201420 1445500
Total Operating Expense 3494180 3123810 2596860 3193730 1874650
Selling/General/Admin. Expenses, Total 997309 886361 875663 964737 717599
Research & Development 633325 526087 455833 492381 368298
Depreciation / Amortization 542443 472915 421864 455420 178617
Unusual Expense (Income) 21593 100290 -265230 189043 -41201
Other Operating Expenses, Total 55443 31309 114422 2384 -2507
Operating Income 533293 445198 600952 97459 222577
Interest Income (Expense), Net Non-Operating -158203 -142628 -234717 -158213 -94965
Other, Net 1
Net Income Before Taxes 375090 302571 366235 -60754 127612
Net Income After Taxes 317038 230166 376171 44290 135080
Minority Interest -21 -107 -166 -49 112
Net Income Before Extra. Items 317017 230059 376005 44241 135192
Net Income 317017 230059 376005 44241 135192
Income Available to Common Excl. Extra. Items 317017 230059 376005 44241 135192
Income Available to Common Incl. Extra. Items 317017 230059 376005 44241 135192
Diluted Net Income 317017 230059 376005 44241 135192
Diluted Weighted Average Shares 1569.87 1577.17 1573.54 1566.2 966.897
Diluted EPS Excluding Extraordinary Items 201.938 145.868 238.955 28.2473 139.82
Dividends per Share - Common Stock Primary Issue 180 180 180 180 180
Diluted Normalized EPS 213.564 194.24 129.394 106.703 112.123
Interest Expense (Income) - Net Operating 2112
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total revenue 1043090 1058620 956156 1096550 1002310
Revenue 1043090 1058620 956156 1096550 1002310
Cost of Revenue, Total 343582 321114 309772 335973 305445
Gross Profit 699507 737504 646384 760578 696862
Total Operating Expense 1092430 890047 867594 949561 897869
Selling/General/Admin. Expenses, Total 252952 248113 254796 262299 248734
Research & Development 183946 162741 160944 174629 154145
Depreciation / Amortization 130742 129423 133224 135576 142366
Unusual Expense (Income) 109500 11243 14898
Other Operating Expenses, Total 71708 28656 -2385 26186 47179
Operating Income -49341 168571 88562 146990 104438
Interest Income (Expense), Net Non-Operating -46638 -33538 -40647 -39837 -39890
Net Income Before Taxes -95980 135033 47915 107153 64549
Net Income After Taxes -47971 89406 31136 119149 61732
Minority Interest -60 -11 -2 -22 10
Net Income Before Extra. Items -48031 89395 31134 119127 61742
Net Income -48031 89395 31134 119127 61742
Income Available to Common Excl. Extra. Items -48030 89395 31134 119127 61742
Income Available to Common Incl. Extra. Items -48030 89395 31134 119127 61742
Diluted Net Income -48030 89395 31134 119127 61742
Diluted Weighted Average Shares 1566.81 1565.04 1583.78 1570.42 1563.73
Diluted EPS Excluding Extraordinary Items -30.6547 57.1199 19.658 75.857 39.4837
Dividends per Share - Common Stock Primary Issue 94 0 90 0 90
Diluted Normalized EPS 14.7721 57.1199 24.2709 82.0233 39.4837
Total Adjustments to Net Income 1 0
Other, Net -1 1
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total Current Assets 2397960 2593640 2712890 2469430 2993040
Cash and Short Term Investments 553704 875000 1002820 653436 725819
Cash & Equivalents 229557 389058 335027 188640 462890
Short Term Investments 324147 485942 667793 464796 262929
Total Receivables, Net 681693 724377 812714 784921 749119
Accounts Receivable - Trade, Net 575430 617517 707487 670708 657681
Total Inventory 986457 853167 753881 759599 919670
Other Current Assets, Total 176102 141098 143478 271476 598429
Total Assets 13957800 13178000 12912300 12821100 13792800
Property/Plant/Equipment, Total - Net 1691230 1582800 1453920 1386370 1331930
Property/Plant/Equipment, Total - Gross 2698980 2453010 2191740 2084120 1971520
Accumulated Depreciation, Total -1007750 -870208 -737818 -697754 -639591
Goodwill, Net 4790720 4407750 4033920 4012530 4240250
Intangibles, Net 4269660 3818540 3909110 4171360 4751170
Long Term Investments 378857 330133 348350 369455 299922
Other Long Term Assets, Total 429328 445150 454110 411948 176463
Total Current Liabilities 2481940 2145730 1773180 2175900 2553050
Accounts Payable 307453 295933 232105 211627 212348
Notes Payable/Short Term Debt 256 285 69 5014 500002
Current Port. of LT Debt/Capital Leases 339344 203708 22084 581803 484944
Other Current Liabilities, Total 1834890 1645800 1518920 1377450 1355760
Total Liabilities 7603630 7495000 7739260 8097610 8610790
Total Long Term Debt 4042740 4141420 4613220 4506490 4766000
Long Term Debt 4042740 4141420 4613220 4506490 4766000
Deferred Income Tax 295178 473145 576542 765079 783356
Minority Interest 549 504 4140 4003 4006
Other Liabilities, Total 783219 734202 772180 646144 504372
Total Equity 6354120 5683020 5173040 4723480 5181980
Common Stock 1676340 1676260 1668140 1668120 1643580
Additional Paid-In Capital 1728830 1708870 1688420 1680290 1650230
Retained Earnings (Accumulated Deficit) 1541150 1479720 1509910 1369970 1595430
Treasury Stock - Common -100317 -116007 -59552 -87463 -57142
Unrealized Gain (Loss) 12470 22068 41983 22891 46380
Other Equity, Total 1495650 912106 324131 69673 303499
Total Liabilities & Shareholders’ Equity 13957800 13178000 12912300 12821100 13792800
Total Common Shares Outstanding 1554.53 1550.36 1563.36 1557.77 1554.78
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 2462070 2472020 2397960 2595950 2745620
Cash and Short Term Investments 333807 368609 553704 726608 830069
Cash & Equivalents 318051 316380 229557 685141 798137
Short Term Investments 15756 52229 324147 41467 31932
Total Receivables, Net 788066 825481 681693 779872 800536
Accounts Receivable - Trade, Net 755327 792895 575430 707318 759894
Total Inventory 1155870 1083370 986457 927286 953450
Other Current Assets, Total 184327 194553 176102 162180 161561
Total Assets 14871900 14792700 13957800 13504700 14588800
Property/Plant/Equipment, Total - Net 1894140 1795320 1691230 1656420 1760330
Goodwill, Net 5301020 5182130 4790720 4690950 4994630
Intangibles, Net 4402420 4514080 4269660 3765760 4187060
Long Term Investments 416364 393529 378857 369469 425766
Other Long Term Assets, Total 395885 435665 429328 426168 475451
Total Current Liabilities 2367620 2501740 2481940 2236810 2391720
Accounts Payable 421078 440924 307453 381109 388616
Notes Payable/Short Term Debt 0 0 256 0 0
Current Port. of LT Debt/Capital Leases 274841 416860 339344 372019 568228
Other Current Liabilities, Total 1671700 1643960 1834890 1483680 1434880
Total Liabilities 7801540 7871690 7603630 7328730 7875920
Total Long Term Debt 4404360 4330250 4042740 3914880 4168420
Long Term Debt 4404360 4330250 4042740 3914880 4168420
Deferred Income Tax 232744 274356 295178 413833 493229
Minority Interest 673 617 549 520 560
Other Liabilities, Total 796141 764719 783219 762681 821992
Total Equity 7070350 6921050 6354120 6175980 6712930
Common Stock 1676500 1676410 1676340 1676330 1676330
Additional Paid-In Capital 1711110 1741940 1728830 1712040 1695540
Retained Earnings (Accumulated Deficit) 1446020 1490100 1541150 1507720 1530200
Treasury Stock - Common -51246 -100255 -100317 -100314 -100313
Unrealized Gain (Loss) 18062 26682 12470 13341 16819
Other Equity, Total 2269900 2086180 1495650 1366860 1894350
Total Liabilities & Shareholders’ Equity 14871900 14792700 13957800 13504700 14588800
Total Common Shares Outstanding 1568.89 1554.57 1554.53 1554.52 1554.52
Property/Plant/Equipment, Total - Gross 2698980
Accumulated Depreciation, Total -1007750
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Net income/Starting Line 317038 230166 376171 44290 109014
Cash From Operating Activities 977156 1123100 1010930 670381 328301
Cash From Operating Activities 664400 583151 559671 583649 272446
Non-Cash Items 327626 252109 12308 172928 39061
Cash Taxes Paid 185966 140423 201687 226768 44909
Cash Interest Paid 108555 108207 107350 127211 34914
Changes in Working Capital -331908 57679 62781 -130486 -92220
Cash From Investing Activities -607102 -198125 393530 292119 -2835700
Capital Expenditures -633689 -186037 -236468 -217710 -134114
Other Investing Cash Flow Items, Total 26587 -12088 629998 509829 -2701580
Cash From Financing Activities -709148 -1070260 -1088350 -1005210 2946240
Financing Cash Flow Items -117732 -108592 -142352 -132804 -71143
Total Cash Dividends Paid -279416 -283665 -283357 -282582 -142952
Issuance (Retirement) of Stock, Net -26929 -77531 -2141 -3737 -1172
Issuance (Retirement) of Debt, Net -285071 -600477 -660504 -586090 3161500
Foreign Exchange Effects 22929 28758 12501 -21766 -31269
Net Change in Cash -316165 -116527 328608 -64479 407571
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 317038 285903 166753 105021 230166
Cash From Operating Activities 977156 683463 305234 84241 1123100
Cash From Operating Activities 664400 502990 326110 158283 583151
Non-Cash Items 327626 218641 140497 51740 252109
Cash Taxes Paid 185966 165066 109217 20855 140423
Cash Interest Paid 108555 86563 52719 22770 108207
Changes in Working Capital -331908 -324071 -328126 -230803 57679
Cash From Investing Activities -607102 -168610 -121920 -94714 -198125
Capital Expenditures -633689 -189609 -138985 -98376 -186037
Other Investing Cash Flow Items, Total 26587 20999 17065 3662 -12088
Cash From Financing Activities -709148 -702548 -267593 -215717 -1070260
Financing Cash Flow Items -117732 -92527 -52761 -22786 -108592
Total Cash Dividends Paid -279416 -268997 -140007 -128873 -283665
Issuance (Retirement) of Stock, Net -26929 -26929 -26929 -26929 -77531
Issuance (Retirement) of Debt, Net -285071 -314095 -47896 -37129 -600477
Foreign Exchange Effects 22929 23141 32720 22485 28758
Net Change in Cash -316165 -164554 -51559 -203705 -116527

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Takeda Pharmaceutical Company Limited Company profile

About Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Financial summary

BRIEF: For the nine months ended 31 December 2021, Takeda Pharmaceutical Co Ltd revenues increased 11% to Y2.696T. Net income applicable to common stockholders increased 35% to Y241.42B. Revenues reflect Intellectual Property And Service Revenue segment increase from Y69.04B to Y210.55B, Pharmaceutical Business segment increase of 5% to Y2.485T, Northern America segment increase of 9% to Y1.297T, Japan segment increase of 22% to Y530.25B.

Equity composition

FY'94-02 WAS were estimated. FY'04 Name changed from Takeda Chemical Industries, Ltd. to Takeda Pharmaceutical Company Limited. All 1&3Q, WAS were estimated and used as O/S. FY'08 Q3 WAS=O/S. FY'11 Q3 DWAS is estimated.

Industry: Pharmaceuticals (NEC)

4階
日本橋本町二丁目1番1号
CHUO-KU
TOKYO-TO 103-8668
JP

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

XRP/USD

0.49 Price
+12.540% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

ETH/USD

3,050.29 Price
+4.390% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

18,006.40 Price
-1.660% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

BTC/USD

64,243.85 Price
+3.580% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading